Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

When cell death goes wrong - scientists gain new insights

Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die. The work may help scientists to eventually develop new treatments for the many common diseases and conditions which occur when cell death goes wrong.

13 Aug 2009

Cannabis Science reports on future plans for cannabis drug trials

Cannabis Science, Inc. (OTCBB: CBIS) has announced that it has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.

12 Aug 2009

Aldose reductase inhibition shows promise for asthma

University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.

11 Aug 2009

STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells

In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation. The researchers report that STAT3 could become a target for cancer therapy, specifically in Glioblastoma multiforme (GBM), a type of malignant and aggressive brain tumor.

11 Aug 2009

Recruitment of new neurons slows when old brain cells kept from dying

Recruitment of new neurons slows when old brain cells kept from dying. Like clockwork, brain regions in many songbird species expand and shrink seasonally in response to hormones.

11 Aug 2009

Epicept files NDA for Ceplene in Canada

EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.

5 Aug 2009

Research points to new targets for melanoma

Recent research has uncovered an unexpected vulnerability in deadly melanoma cells that, when exploited, can cause the cancer cells to turn against themselves.

3 Aug 2009

New clues about the roots of neurological disease

Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion, according to new research led by St. Jude Children's Research Hospital scientists.

27 Jul 2009

Research builds on previous Par-4 study that produced cancer-resistant mouse

Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.

26 Jul 2009

Caspase-8 protein plays an important role in proliferation and invasion of cancer cells

Scientists at Burnham Institute for Medical Research have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues. The study was published in the journal Cancer Research on June 15.

24 Jul 2009

Estrogen can reduce stroke damage by inactivating a tumor-suppressing protein

Estrogen can halt stroke damage by inactivating a tumor-suppressing protein known to prevent many cancers, Medical College of Georgia researchers say.

17 Jul 2009

New insight into apoptosis

A study by Nanyang Technological University (NTU)'s Assistant Professor Li Hoi Yeung, Assistant Professor Koh Cheng Gee and their team have made an important contribution to the understanding of the process that cells go through when they die. This process known as 'apoptosis' or programmed cell death, is a normal process in the human body which removes perhaps a million cells a second.

14 Jul 2009

Controlling the fate of cells

A protein found in cells has been shown to play a pivotal role in determining whether a cell lives or dies.

13 Jul 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Novel light-sensitive compounds show promise for photodynamic cancer therapy

Chemists at the University of California, Santa Cruz, have developed novel compounds that show promise for photodynamic cancer therapy, which uses light-activated drugs to kill tumor cells.

17 Jun 2009

Discovery in dendritic cell signalling pathways pave way for new therapeutic targets

Scientists from A*STAR's Singapore Immunology Network (SIgN) and the University of Milano-Bicocca, Italy, have discovered another signaling pathway for the activation and apoptosis, or programmed cell death, of dendritic cells. This discovery was published in the advanced online publication of Nature on 15 Jun 2009.

15 Jun 2009

Resveratrol shows potential for significant health benefits

The benefits of alcohol are all about moderation. Low to moderate drinking - especially of red wine - appears to reduce all causes of mortality, while too much drinking causes multiple organ damage. A mini-review of recent findings on red wine's polyphenols, particularly one called resveratrol, will be published in the September issue of Alcoholism: Clinical & Experimental Research; the review is also available at Early View.

12 Jun 2009

New lung cancer therapy with vaporized viral vector shows promise

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

9 Jun 2009

Cisplatin doubles lung cancer survival time in mice

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.

9 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009